Exegenesis Bio pockets over USD20m in Series B round led by Legend Capital

On August 3, Exegenesis Bio, a gene therapy drug developer, successfully completes its Series B financing round worth more than 20 million US dollars.

On August 3, Exegenesis Bio, a gene therapy drug developer, successfully completes its Series B financing round worth more than 20 million US dollars.

The round was led by Legend Capital, and the proceeds will be used to advance the clinical and research and development of the company’s multiple gene therapy pipelines.

Founded in July 2019 and based in Hangzhou, Exegenesis Bio is an innovative pharmaceutical company dedicated to providing accessible gene therapies to the global market.

The company mainly focuses on the research and development of gene therapy drugs and provides a unique gene therapy platform for a variety of major genetic diseases, enabling clients to receive effective treatment for genetic diseases.

The founding team of Exegenesis has extensive experience in the development of gene and cell therapies, having worked for more than 15 years at several leading gene therapy companies in the United States.

Dr. Wu Zhenhua, founder and CEO, said, “Exegenesis Bio is innovating in various aspects from viral vector design and construction, pre-clinical trials, process development, GMP production, and clinical trial design, and will build a complete industry chain from early stage R&D to production and clinical stage.”

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/08/04/exegenesis-bio-pockets-over-usd20m-in-series-b-round-led-by-legend-capital/.

Leave a Reply

Please Login to Comment